Repare Therapeutics Announces Shareholder Meeting for Acquisition Approval

New activity is brewing for Repare Therapeutics ( (RPTX) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential Repare Therapeutics has announced a special meeting for shareholders on January 16, 2026, to vote on a proposed arrangement with XenoTherapeutics, Inc. The arrangement involves the acquisition of all outstanding common shares by Xeno Acquisition Corp., with shareholders receiving cash and contingent value rights. If approved, the company will become private, delist from Nasdaq, and cease reporting to the SEC. The board recommends voting in favor of the arrangement, citing strategic benefits and fairness of the transaction. The most recent analyst rating on (RPTX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Repare Therapeutics stock, see the RPTX Stock Forecast page. Spark’s Take on RPTX Stock According to Spark, TipRanks’ AI Analyst, RPTX is a Neutral. Repare Therapeutics’ overall stock score is driven by positive technical indicators and promising corporate developments, despite financial challenges and poor valuation metrics. The company’s strong cash position and recent trial data provide a foundation for potential future improvements. To see Spark’s full report on RPTX stock, click here. More about Repare Therapeutics Repare Therapeutics Inc. is a biotechnology company based in St-Laurent, Québec, Canada. The company is involved in the development of precision oncology therapies, focusing on synthetic lethality to target specific genetic vulnerabilities in cancer cells. Average Trading Volume: 534,202 Technical Sentiment Signal: Sell Current Market Cap: $92.25M